Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) EBIT Margin (2020 - 2022)

Historic EBIT Margin for Immuneering (IMRX) over the last 3 years, with Q4 2022 value amounting to 3073627.91%.

  • Immuneering's EBIT Margin fell 30677648900.0% to 3073627.91% in Q4 2022 from the same period last year, while for Sep 2023 it was 12328770.77%, marking a year-over-year decrease of 123191132400.0%. This contributed to the annual value of 16325.77% for FY2022, which is 146966100.0% down from last year.
  • As of Q4 2022, Immuneering's EBIT Margin stood at 3073627.91%, which was down 30677648900.0% from 34362.04% recorded in Q3 2022.
  • Immuneering's 5-year EBIT Margin high stood at 644.66% for Q3 2020, and its period low was 3073627.91% during Q4 2022.
  • Moreover, its 3-year median value for EBIT Margin was 1772.01% (2021), whereas its average is 285392.02%.
  • Per our database at Business Quant, Immuneering's EBIT Margin tumbled by -4606000bps in 2021 and then tumbled by 2000000000bps in 2022.
  • Quarter analysis of 3 years shows Immuneering's EBIT Margin stood at 877.56% in 2020, then tumbled by -568bps to 5863.02% in 2021, then plummeted by -52324bps to 3073627.91% in 2022.
  • Its last three reported values are 3073627.91% in Q4 2022, 34362.04% for Q3 2022, and 12334.43% during Q2 2022.